CN1477194A - A polypeptide-human transpasase 105 and polynucleotide coding said polypetide - Google Patents

Abstract

The present invention discloses a polypeptide-human transposes 105, polynucleotide for coding said polypeptide and method for producing said polypeptide by means of DNA recombination technology. Said invention also discloses the method for curing several diseases, such as malignant tumor, hematopathy, HIV infection, immunological diseases and various inflammations by using said polypeptide. It also discloses the agonist for resisting said polypeptide and its therapeutic action. It also discloses the application of polynucleotide coding this novel human transposase 105.

Description

The polynucleotide of a kind of polypeptide-human transposase 105 and this peptide species of coding

Technical field

The invention belongs to biological technical field, specifically, the invention describes a kind of polypeptide-human transposase 105, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.

Background technology

The Mariner transposon belongs to the mariner/Tc1 superfamily in the transposable element, is distributed widely in the animal bodies such as insect, nematode, flatworm and the mankind, and be one of the simplest eucaryon transposon.Their mean length is about 1.3kb, comprises an open reading frame (ORF), coding transposase albumen, and two ends have the about 30bp of inverted repeats (ITRs).

The Mariner transposon moves on the DNA intermediate with the mechanism of a kind of " shearing and stickup ", and the result is that transposon is cut down from original place, and inserts genomic new location.This process has two key factors: the one, need activated transposase, and the 2nd, the inverted repeats of transposon end (ITRs), transposase identification and mobile ITRs.The Mariner transposon always is incorporated in the TA dinucleotide sequence, and this sequence is replicated during insertion.Confirm that recently the mariner transposase behind the purifying can effectively mediate transposition external, and the transposase function realizes need not the participation of host specific sex factor.

The Tc1/mariner superfamily comprises Tc1, mar iner and pogo transposon, and length is about 1300-2400bp, comprises the gene of a coding transposase, and there is ITPs at two ends.Though some difference (transposase protein 15 % homology) are arranged on motif, and superfamily member has same origin, and identical structure and molecule swivel base mechanism are arranged.

The main structural-functional analysis of transposase concentrates on the DNA land of N-terminal.

Tc1 and mariner transposase have dual DNA land, comprise two HTH structures, and first is similar to the paired district of some transcription factors, and second is in the homology DNA land.The Pogo transposase only contains single HTH structure.Nucleic acid signal for locating (NLS) is overlapping with DNA land part, plays regulating and controlling effect in transposition.Another main region is a catalytic domain, the special construction that DD35D or DD35E are arranged, linked to each other with one section " D35D " or " D35E " zone by a conservative Asp, this zone comprises conservative arginine and glutaminic acid residue, and generally there are 35 conservative relatively amino-acid residues the centre.

There is ITPs at the transposon two ends, comprise the transposase binding site.In the different members of Tc1/mariner superfamily, the length of ITPs and the quantity of binding site and type be difference to some extent all.Tc1 and mariner are the simplest, ITPs＜100bp, and each only contains single transposase binding site.Binding site also is a dual structure, and 5 ' end parts is discerned by homologous region, and 3 ' end parts and district's interaction in pairs.

Transposase and ITRs participate in a series of molecularity in transposition, cause transposon to cut down from former sequence, are incorporated into again in the different locus (to shear and the stickup effect).

Transposon two ends after shearing action produce a pair of staggered double-stranded DNA breach, and this stagger may form transposon " footprint " in karyomit(e) or other dna molecular.In some cases, " footprint " may be the direct bonded result of staggered end.The Tc1/mariner transposon generally stay 2-3bp's " footprint ".Because integrating remark is subsequently finished by 3 ' end, the size that the site only influences the strand breach that needs reparation is cut in 5 ' end-grain cutting, and the final product of transposition is not had influence.

Most Tc1/mariner transposons are integrated into TA dinucleotide sequence.The sequence of TA side may be discerned target sequence to transposase and exert an influence, and in addition, the structure of DNA also can influence the activity of transposon.

Except that transposase, the Tc1/mariner transposon does not need other albumen to participate in transposition, and this shows that they do not have strict host's restriction.

According to amino acid homology result relatively, polypeptide of the present invention is accredited as a kind of new people's transposase 105 by deduction.

Summary of the invention

An object of the present invention is to provide isolating new polypeptide-human transposase 105 with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of this polypeptide of coding.

Another object of the present invention provides the recombinant vectors of the polynucleotide that contain coding people transposase 105.

Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain coding people transposase 105.

Another object of the present invention provides the method for producing people's transposase 105.

Another object of the present invention provides the antibody at polypeptide-human transposase 105 of the present invention.

Another object of the present invention has provided at the simulated compound of polypeptide-human transposase 105 of the present invention, antagonist, agonist, inhibitor.

Another object of the present invention provides the method for the unusual relevant disease of diagnoses and treatment and people's transposase 105.

In a first aspect of the present invention, novel isolated people's transposase 105 is provided, this polypeptide is the people source, and it comprises: have＜polypeptide of 210〉2 aminoacid sequences or its conservative property variation polypeptide or its active fragments or its reactive derivative, analogue.Preferably, this polypeptide is to have＜polypeptide of 210〉2 aminoacid sequences.

In a second aspect of the present invention, the polynucleotide of isolating these polypeptide of coding are provided, these polynucleotide comprise a nucleotide sequence, and this nucleotide sequence is shown at least 98% homogeny with a kind of nucleotides sequence that is selected from down group: (a) polynucleotide of the above-mentioned people's transposase 105 of coding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, this polynucleotide encoding have＜210〉2 shown in the polypeptide of aminoacid sequence.More preferably, the sequence of these polynucleotide is be selected from down group a kind of: (a) have＜210〉1 in the sequence of 181-3039 position; (b) have＜210〉1 in the sequence of 1-3351 position.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating people's transposase 105 " is meant that people's transposase 105 is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying people transposase 105 of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of people's transposase 105 polypeptide can be used amino acid sequence analysis.

The invention provides a kind of polypeptide-human transposase 105, it is basically by＜210〉aminoacid sequence shown in 2 forms.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises fragment, derivative and the analogue of people's transposase 105.As used herein, term " fragment ", " derivative " and " analogue " are meant biological function or the active polypeptide that keeps people's transposase of the present invention 105 identical basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.

The invention provides isolating nucleic acid (polynucleotide), substantially by coding have＜polynucleotide of the polypeptide of 210〉2 aminoacid sequences form.Polynucleotide sequence of the present invention comprises＜210〉1 nucleotide sequence.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 3351 bases, its open reading frame (181--3039) 952 amino acid of having encoded.Find relatively that according to amino acid sequence homologous this polypeptide and people's KIAA0686 albumen has 97% homology, deducibility goes out the 26S Proteasome Structure and Function that this people's transposase 105 has people's KIAA0686 protein similar.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in＜210〉1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has＜210〉2 protein or polypeptide, but with the differentiated nucleotide sequence of coding region sequence shown in＜210〉1.

The polynucleotide of the mature polypeptide of coding＜210〉2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And, the polypeptide of interfertile polynucleotide encoding and＜210〉and the mature polypeptide shown in 2 has identical biological function and activity.

The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding people transposase 105.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

The special polynucleotide sequence of coding people transposase 105 of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.

Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration people transposase 105; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect the protein product of people's transposase 105 genetic expressions and can use immunological technique such as Wcstcrn blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.

Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with the carrier of the present invention or transposase 105 encoding sequences of directly choosing, and the method that produces polypeptide of the present invention through recombinant technology.

Among the present invention, the polynucleotide sequence of coding people transposase 105 can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.

Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains coding people transposase 105 and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, a LaboratoryManual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage _LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.

Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.

Among the present invention, the polynucleotide of coding people transposase 105 or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Rowes melanoma cells etc.

Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.

By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce people's transposase 105 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:

(1). with the polynucleotide (or varient) of everybody transposase 105 of coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). in suitable medium, cultivate host cell;

(3). separation, protein purification from substratum or cell.

In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.

Transposon can be used as transgene carrier, new phenotype is brought in the karyomit(e), or destroy oncogene to insert mutation effect.

The Tc1/mariner transposon has been compared some potential advantages with existing gene transfer technique.Transposon-mediated stable single copy gene is integrated into karyomit(e), but transgenic cell or the tissue in long-term expression.Though have the frequency of the transposition of the segmental transposon of big insertion to descend, still can carry out transposition greater than the fragment of 14kb.Therefore, high swivel base frequency just is not under the vital condition in experiment, and transposon has the carrier of strict restriction that remarkable advantages is arranged than retrovirus, adenovirus etc. to inserting clip size.Another useful feature is the participation that transposition only needs transposase, and therefore, the site of swivel base and opportunity can be regulated and control by the expression of transposase simply.

Polypeptide of the present invention is considered to can be used for diagnosis and treats a lot of diseases, includes but not limited to following: malignant tumour, endocrine system disease, nervous system disorders, immunological disease, people's acquired immune deficiency syndrome (AIDS).

The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of (antagonist) people transposase 105.Agonist improves people's transposase 105 biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can in the presence of medicine, the film preparation of mammalian cell or expressing human transposase 105 be cultivated with people's transposase 105 of mark.Measure the medicine raising then or check this interactional ability.

The antagonist of people's transposase 105 comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of people's transposase 105 can combine and eliminate its function with people's transposase 105, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.

In screening during as the compound of antagonist, people's transposase 105 can be added during bioanalysiss measure, determine to interactional influence between people's transposase 105 and its acceptor whether compound is antagonist by measuring compound.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with people's transposase 105 bonded peptide molecules obtains.During screening, generally tackle people's transposase 105 molecules and carry out mark.

The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at people's transposase 105 antigenic determinants.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

Can the choose method of transposase 105 direct injection immune animals (as rabbit, mouse, rat etc.) of the production of polyclonal antibody obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of preparation people transposase 105 include but not limited to hybridoma technology (Kohler andMilstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-people's transposase 105.

The antibody of anti-people's transposase 105 can be used in the immunohistochemistry technology, detects the people's transposase 105 in the biopsy specimen.

With the also available labelled with radioisotope of people's transposase 105 bonded monoclonal antibodies, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of people's transposase 105 high-affinities can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing people's transposase 105 positive cells.

The disease that antibody among the present invention can be used for treating or prevention and people's transposase 105 are relevant.The antibody that gives suitable dosage can stimulate or block the generation or the activity of people's transposase 105.

The invention still further relates to the diagnostic testing process of quantitative and detection and localization people transposase 105 levels.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.People's transposase 105 levels that detected in the test can be with laying down a definition the importance of people's transposase 105 in various diseases and be used to the disease of diagnosing people's transposase 105 to work.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.

The polynucleotide of coding people transposase 105 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of people's transposase 105 or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for people's transposase 105 of expressing variation, to suppress endogenic people's transposase 105 activity.For example, a kind of people's transposase 105 of variation can be the people's transposase 105 that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of 105 expression of people's transposase or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding people transposase 105 are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding people transposase 105 is found in existing document (Sambrook, et al.).The polynucleotide of reorganization coding people transposase 105 can be packaged in the liposome and be transferred in the cell in addition.

Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Suppress the oligonucleotide (comprising sense-rna and DNA) of people's transposase 105mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

The polynucleotide of coding people transposase 105 can be used for the diagnosis with the relative disease of people's transposase 105.The unconventionality expression of the expression that the polynucleotide of coding people transposase 105 can be used for detecting people's transposase 105 people's transposase 105 whether or under morbid state.As the dna sequence dna of the people's transposase 105 of encoding can be used for biopsy specimen is hybridized to judge the expression situation of people's transposase 105.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Personnel selection transposase 105 special primers carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect people's transposase 105.

The sudden change that detects people's transposase 105 genes also can be used for diagnosing the relevant disease of people's transposase 105.The form of people's transposase 105 sudden change comprises that the point mutation compared with normal wild type people transposase 105 dna sequence dnas, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritancein Man (can by with the online acquisition of Johns Hopkins Univcrsity Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.People's transposase 105 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to people's transposase 105 of patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

Description of drawings

Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.

Fig. 1 is the proteic amino acid sequence homology comparison diagram of inventor's transposase 105 and people's KIAA0686.The top sequence is people's transposase 105, and the below sequence is people's a KIAA0686 albumen.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".

Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating people's transposase 105.105kDa is proteinic molecular weight.The arrow indication is isolated protein band.

Embodiment

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Embodiment 1: the clone of people's transposase 105

Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qicgcnc company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Pcrkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 0196c09 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 0196c09 clone is 3351bp (as＜210〉1 shown in), from 181bp to 3039bp the open reading frame (ORF) of a 2859bp arranged, the new protein of encoding (as＜210〉2 shown in).We are with this clone's called after pBS-0196c09, and the name of encoded protein matter is people's transposase 105.

Embodiment 2:cDNA clone's homology retrieval

With the sequence and the encoded protein sequence thereof of people's transposase 105 of the present invention, with Blast program (BasiclocalAlignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with people's transposase 105 homologys of the present invention is a kind of known people's KIAA0686 albumen, and its encoded protein number is AB014586 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 97%; Similarity is 98%.Embodiment 3: with the gene of RT-PCR method clones coding people transposase 105

Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:

Primer1：5’-GAAGAACAAACTCTTACCCTTAT-3’?(<210>3)

Primer2：5’-TTCTATTGCTTTATTGATTATTA-3’?(<210>4)

Primer1 for to be positioned at＜the forward sequence that begins of 1bp of 210〉15 ' end;

Primer2 be＜210〉1 in 3 ' end reverse sequence.

The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/LTris-Cl, (pH8.5), 1.5mmol/L MgCl ₂, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows the dna sequence dna and＜210 of PCR product〉1-3351bp shown in 1 is identical.Embodiment 4:Northern blotting analyst transposase 105 expression of gene:

Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- ³²P dATP prepares by random priming ³²The dna probe of P-mark.Used dna probe is people's transposase 105 coding region sequences (181bp to 3039bp) of pcr amplification shown in Figure 1.Will ³²The probe of P-mark (about 2 * 10 ⁶Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH ₂PO ₄(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with PhosphorImager.Embodiment 5: the vivoexpression of recombinant human transposase 105, separation and purifying

According to＜210〉1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:

Primer3：5’-CCCGGATCCATGGTTATTATTACAGGGAGTGAC-3’(<210>5)

Primer4：5’-CCCCTCGAGCTCAGTCGAATGGTTAGTGAGGAG-3’(<210>6)

5 ' end of these two sections primers contains BamHI and XboI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, BamHI and XboI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-0196c09 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-0196c09 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with BamIII and XboI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-0196c09) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-0196c09) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein people transposase 105 of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 105kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end are identical with 15 amino-acid residues of N-end shown in＜210〉2 as a result.Embodiment 6 anti-people's transposase 105 production of antibodies

Synthesize following people's transposase 105 specific polypeptide with Peptide synthesizer (PE company product):

NH ₂-Met-Val-Ile-Ile-Thr-Gly-Ser-Asp-Leu-His-Asn-Gly-Ile-Ile-Gly-COOH。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with people's transposase 105 specifically.

＜110〉＜120〉--105＜130〉0196c09＜160〉6＜170〉PatentIn version 3.1＜210〉1＜211〉3351＜212〉DNA＜213〉Homo sapiens＜220〉＜221〉CDS＜222〉 ( 181 ) .. ( 3039 )＜223〉＜400〉1gaagaacaaa ctcttaccct tatattccta gatggagaaa gagaacgtaa agtatcagtt 60caaattttgg atgatgatga gcctgagggg caggaattct tctacgtgtt tctcgcaaac 120cctcaagggg gagcacagat tgtggagggg aaggatgata ctggatttgc agcttttgcc 180atg gtt att att aca ggg agt gac ctt cac aat ggc atc ata gga ttc 228Met Val Ile Ile Thr Gly Ser Asp Leu His Asn Gly Ile Ile Gly Phe1 5 10 15agt gag gag tcc cag agt gga cta gaa ctc agg gaa gga gct gtt atg 276Ser Glu Glu Ser Gln Ser Gly Leu Glu Leu Arg Glu Gly Ala Val Met

20 25 30aga?aga?ttg?cac?ctt?att?gtc?aca?aga?cag?cca?aac?agg?gcc?ttt?gaa 324Arg?Arg?Leu?His?Leu?Ile?Val?Thr?Arg?Gln?Pro?Asn?Arg?Ala?Phe?Glu

35 40 45gat?gtc?aag?gtc?ttt?tgg?cga?gtc?aca?ctt?aac?aaa?aca?gtt?gtc?gtg 372Asp?Val?Lys?Val?Phe?Trp?Arg?Val?Thr?Leu?Asn?Lys?Thr?Val?Val?Val

50 55 60ctc?cag?aag?gat?ggg?gta?aac?ctg?atg?gag?gaa?ctt?cag?tct?gtg?tca 420Leu?Gln?Lys?Asp?Gly?Val?Asn?Leu?Met?Glu?Glu?Leu?Gln?Ser?Val?Ser65 70 75 80ggg?acc?aca?acc?tgt?aca?atg?ggt?caa?aca?aaa?tgc?ttt?atc?agc?att 468Gly?Thr?Thr?Thr?Cys?Thr?Met?Gly?Gln?Thr?Lys?Cys?Phe?Ile?Ser?Ile

85 90 95gaa?ctc?aaa?cca?gaa?aag?gta?cca?cag?gtt?gaa?gtg?tat?ttt?ttt?gtg 516Glu?Leu?Lys?Pro?Glu?Lys?Val?Pro?Gln?Val?Glu?Val?Tyr?Phe?Phe?Val

100 105 110gaa?cta?tat?gaa?gct?act?gct?gga?gca?gca?ata?aac?aac?agt?gcc?aga 564Glu?Leu?Tyr?Glu?Ala?Thr?Ala?Gly?Ala?Ala?Ile?Asn?Asn?Ser?Ala?Arg

115 120 125ttc?gca?cag?att?aaa?atc?tta?gaa?agt?gat?gaa?tct?caa?agc?ctt?gtg 612Phe?Ala?Gln?Ile?Lys?Ile?Leu?Glu?Ser?Asp?Glu?Ser?Gln?Ser?Leu?Val

130 135 140tat?ttt?tct?gtg?ggt?tct?cgg?ctg?gca?gtg?gct?cac?aag?aag?gcc?act 660Tyr?Phe?Ser?Val?Gly?Ser?Arg?Leu?Ala?Val?Ala?His?Lys?Lys?Ala?Thr145 150 155 160tta?atc?agt?ctg?cag?gtg?gcc?aga?gat?tct?ggg?aca?gga?cta?atg?atg 708Leu?Ile?Ser?Leu?Gln?Val?Ala?Arg?Asp?Ser?Gly?Thr?Gly?Leu?Met?Met

165 170 175tct?gtt?aac?ttt?agt?acc?cag?gag?ttg?agg?agt?gct?gaa?aca?att?ggt 756Ser?Val?Asn?Phe?Ser?Thr?Gln?Glu?Leu?Arg?Ser?Ala?Glu?Thr?Ile?Gly

180 185 190cgt?acc?atc?ata?tct?cca?gct?att?tct?gga?aag?gat?ttt?gtg?ata?act 804Arg?Thr?Ile?Ile?Ser?Pro?Ala?Ile?Ser?Gly?Lys?Asp?Phe?Val?Ile?Thr

195 200 205gaa?ggc?aca?ttg?gtc?ttt?gaa?cct?ggc?cag?aga?agc?act?gta?ttg?gat 852Glu?Gly?Thr?Leu?Val?Phe?Glu?Pro?Gly?Gln?Arg?Ser?Thr?Val?Leu?Asp

210 215 220gtc?atc?cta?acg?cca?gag?aca?gga?tct?tta?aat?tca?ttt?cct?aaa?cgc 900Val?Ile?Leu?Thr?Pro?Glu?Thr?Gly?Ser?Leu?Asn?Ser?Phe?Pro?Lys?Arg225 230 235 240ttc?cag?att?gtc?ctt?ttt?gac?cca?aaa?ggt?ggt?gcc?aga?att?gat?aaa?948Phe?Gln?Ile?Val?Leu?Phe?Asp?Pro?Lys?Gly?Gly?Ala?Arg?Ile?Asp?Lys

245 250 255gtg?tat?ggg?act?gcc?aac?atc?act?ctt?gtc?tca?gat?gca?gat?tcg?cag 996Val?Tyr?Gly?Thr?Ala?Asn?Ile?Thr?Leu?Val?Ser?Asp?Ala?Asp?Ser?Gln

260 265 270gcc?att?tgg?ggg?ctt?gca?gat?cag?cta?cat?cag?cct?gtg?aat?gat?gat 1044Ala?Ile?Trp?Gly?Leu?Ala?Asp?Gln?Leu?His?Gln?Pro?Val?Asn?Asp?Asp

275 280 285att?ctc?aac?aga?gtg?ctc?cat?acc?atc?agc?atg?aaa?gtg?gcc?aca?gaa 1092Ile?Leu?Asn?Arg?Val?Leu?His?Thr?Ile?Ser?Met?Lys?Val?Ala?Thr?Glu

290 295 300aac?aca?gat?gaa?caa?ctc?agt?gcc?atg?atg?cat?tta?ata?gaa?aag?ata 1140Asn?Thr?Asp?Glu?Gln?Leu?Ser?Ala?Met?Met?His?Leu?Ile?Glu?Lys?Ile305 310 315 320act?act?gaa?gga?aaa?att?caa?gct?ttc?agt?gtt?gcc?agc?cga?act?ctt 1188Thr?Thr?Glu?Gly?Lys?Ile?Gln?Ala?Phe?Ser?Val?Ala?SerArg?Thr?Leu

325 330 335ttc?tat?gag?att?ctt?tgt?tct?ctt?att?aac?cca?aag?cgc?aag?gac?act 1236Phe?Tyr?Glu?Ile?Leu?Cys?Ser?Leu?Ile?Asn?Pro?Lys?Arg?Lys?Asp?Thr

340 345 350agg?gga?ttc?agt?cac?ttt?gct?gaa?gtg?act?gag?aat?ttt?gcc?ttt?tct 1284Arg?Gly?Phe?Ser?His?Phe?Ala?Glu?Val?Thr?Glu?Asn?Phe?Ala?Phe?Ser

355 360 365ctg?ctg?act?aat?gtt?act?tgc?ggc?tct?cct?ggt?gaa?aaa?agc?aaa?acc 1332Leu?Leu?Thr?Asn?Val?Thr?Cys?Gly?Ser?Pro?Gly?Glu?Lys?Ser?Lys?Thr

370 375 380atc?ctt?gat?agt?tgc?cca?tat?ttg?tca?ata?ttg?gct?ctt?cac?tgg?tat 1380Ile?Leu?Asp?Ser?Cys?Pro?Tyr?Leu?Ser?Ile?Leu?Ala?Leu?His?Trp?Tyr385 390 395 400cct?cag?caa?atc?aat?gga?cac?aag?ttt?gaa?gga?aag?gaa?gga?gat?tac 1428Pro?Gln?Gln?Ile?Asn?Gly?His?Lys?Phe?Glu?Gly?Lys?Glu?Gly?Asp?Tyr

405 410 415att?cga?att?cca?gag?agg?cta?ctg?gat?gtc?cag?gat?gca?gaa?ata?atg 1476Ile?Arg?Ile?Pro?Glu?Arg?Leu?Leu?Asp?ValGln?Asp?Ala?Glu?Ile?Met

420 425 430gct?ggg?aaa?agt?aca?tgt?aaa?tta?gtc?cag?ttt?aca?gag?tat?agc?agc 1524Ala?Gly?Lys?Ser?Thr?Cys?Lys?Leu?Val?Gln?Phe?Thr?Glu?Tyr?Ser?Ser

435 440 445caa?cag?tgg?ttt?ata?agt?gga?aac?aat?ctt?cct?acc?cta?aaa?aat?aag 1572Gln?Gln?Trp?Phe?Ile?Ser?Gly?Asn?Asn?Leu?Pro?Thr?Leu?Lys?Asn?Lys

450 455 460gta?tta?tct?ttg?agt?gtg?aaa?ggt?cag?agt?tca?caa?ctc?ctg?act?aat 1620Val?Leu?Ser?Leu?Ser?Val?Lys?Gly?Gln?Ser?Ser?Gln?Leu?Leu?Thr?Asn465 470 475 480gac?aat?gag?gtt?ctc?tac?agg?att?tat?gct?gct?gag?cct?aga?att?att 1668Asp?Asn?Glu?Yal?Leu?Tyr?Arg?Ile?Tyr?Ala?Ala?Glu?Pro?Arg?Ile?Ile

485 490 495cct?cag?aca?tct?ctg?tgt?ctc?ctt?tgg?aat?cag?gct?gct?gca?agc?tgg 1716Pro?Gln?Thr?Ser?Leu?Cys?Leu?Leu?Trp?Asn?Gln?Ala?Ala?Ala?Ser?Trp

500 505 510ttg?tct?gac?agt?cag?ttt?tgc?aaa?gtg?gtt?gag?gaa?act?gca?gac?tat 1764Leu?Ser?Asp?Ser?Gln?Phe?Cys?Lys?Val?Val?Glu?Glu?Thr?Ala?Asp?Tyr

515 520 525gtg?gaa?tgt?gcc?tgt?tca?cac?atg?tct?gtg?tat?gct?gtc?tat?gct?cgg 1812Val?Glu?Cys?Ala?Cys?Ser?His?Met?Ser?Val?Tyr?Ala?Val?Tyr?Ala?Arg

530 535 540act?gac?aac?ttg?tct?tca?tac?aat?gaa?gcc?ttc?ttc?act?tct?gga?ttt 1860Thr?Asp?Asn?Leu?Ser?Ser?Tyr?Asn?Glu?Ala?Phe?Phe?Thr?Ser?Gly?Phe545 550 555 560ata?tgt?atc?tca?ggt?ctt?tgc?ttg?gct?gtt?ctt?tcc?cat?atc?ttc?tgt 1908Ile?Cys?Ile?Ser?Gly?Leu?Cys?Leu?Ala?Val?Leu?Ser?His?Ile?Phe?Cys

565 570 575gcc?agg?tac?tcc?atg?ttt?gca?gct?aaa?ctt?ctg?act?cac?atg?atg?gca 1956Ala?Arg?Tyr?Set?Met?Phe?Ala?Ala?Lys?Leu?Leu?Thr?His?Met?Met?Ala

580 585 590gcc?agc?tta?ggt?aca?cag?att?cta?ttt?ctg?gcg?tct?gca?tac?gca?agt 2004Ala?Ser?Leu?Gly?Thr?Gln?Ile?Leu?Phe?Leu?Ala?Ser?Ala?Tyr?Ala?Ser

595 600 605ccc?caa?ctc?gct?gag?gag?agc?tgt?tca?gct?atg?gct?gct?gtc?aca?cat 2052Pro?Gln?Leu?Ala?Glu?Glu?Ser?Cys?Ser?Ala?Met?Ala?Ala?Val?Thr?His

610 615 620tac?ctg?tat?ctt?tgc?cag?ttt?agc?tgg?atg?ctc?att?cag?tct?gtg?aat 2100Tyr?Leu?Tyr?Leu?Cys?Gln?Phe?Ser?Trp?Met?Leu?Ile?Gln?Ser?Val?Asn625 630 635 640ttc?tgg?tac?gtg?ctg?gtg?atg?aat?gat?gag?cac?aca?gag?agg?cga?tat 2148Phe?Trp?Tyr?Val?Leu?Val?Met?Asn?Asp?Glu?His?Thr?Glu?Arg?Arg?Tyr

645 650 655ctg?ctg?ttt?ttc?ctt?ctg?agt?tgg?gga?cta?cca?gct?ttt?gtg?gtg?att 2196Leu?Leu?Phe?Phe?Leu?Leu?Ser?Trp?Gly?Leu?Pro?Ala?Phe?Val?Val?Ile

660 665 670ctc?ctc?ata?gtt?att?ttg?aaa?gga?atc?tat?cat?cag?agc?atg?tca?cag 2244Leu?Leu?Ile?Val?Ile?Leu?Lys?Gly?Ile?Tyr?His?Gln?Ser?Met?Ser?Gln

675 680 685atc?tat?gga?ctc?att?cat?ggt?gac?ctg?tgt?ttt?att?cca?aac?gtc?tat 2292Ile?Tyr?Gly?Leu?Ile?His?Gly?Asp?Leu?Cys?Phe?Ile?Pro?Asn?Val?Tyr

690 695 700gct?gct?ttg?ttc?act?gca?gct?ctt?gtt?cct?ttg?acg?tgc?ctc?gtg?gtg 2340Ala?Ala?Leu?Phe?Thr?Ala?Ala?Leu?Val?Pro?Leu?Thr?Cys?Leu?Val?Val705 710 715 720gtg?ttc?gtg?gtg?ttc?atc?cat?gcc?tac?cag?gtg?aag?cca?cag?tgg?aaa 2388Val?Phe?Val?Val?Phe?Ile?His?Ala?Tyr?Gln?Val?Lys?Pro?Gln?Trp?Lys

725 730 735gca?tat?gat?gat?gtc?ttc?aga?gga?agg?aca?aat?gct?gca?gaa?att?cca 2436Ala?Tyr?Asp?Asp?Val?Phe?Arg?Gly?Arg?Thr?Asn?Ala?Ala?Glu?Ile?Pro

740 745 750ctg?att?tta?tat?ctc?ttt?gct?ctg?att?tcc?gtg?aca?tgg?ctt?tgg?gga 2484Leu?Ile?Leu?Tyr?Leu?Phe?Ala?Leu?Ile?Ser?Val?Thr?Trp?Leu?Trp?Gly

755 760 765gga?cta?cac?atg?gcc?tac?aga?cac?ttc?tgg?atg?ttg?gtt?ctc?ttt?gtc 2532Gly?Leu?His?Met?Ala?Tyr?Arg?His?Phe?Trp?Met?Leu?Val?Leu?Phe?Val

770 775 780att?ttc?aac?agt?ctg?cag?gga?ctt?tat?gtt?ttc?atg?gtt?tat?ttc?att 2580Ile?Phe?Asn?Ser?Leu?Gln?Gly?Leu?Tyr?Val?Phe?Met?Val?Tyr?Phe?Ile785 790 795 800tta?cac?aac?caa?atg?tgt?tgc?cct?atg?aag?gcc?agt?tac?act?gtg?gaa 2628Leu?His?Asn?Gln?Met?Cys?Cys?Pro?Met?Lys?Ala?Ser?Tyr?Thr?Val?Glu

805 810 815atg?aat?ggg?cat?cct?gga?ccc?agc?aca?gcc?ttt?ttc?acg?ccc?ggg?agt 2676Met?Asn?Gly?His?Pro?Gly?Pro?Ser?Thr?Ala?Phe?Phe?Thr?Pro?Gly?Ser

820 825 830gga?atg?cct?cct?gct?gga?ggg?gaa?atc?atc?aag?tcc?acc?cag?aat?ctc 2724Gly?Met?Pro?Pro?Ala?Gly?Gly?Glu?Ile?Ile?Lys?Ser?Thr?Gln?Asn?Leu

835 840 845atc?ggt?gct?atg?gag?aag?gtg?cca?cct?gac?tgg?gag?aga?gca?tcc?ttc 2772Ile?Gly?Ala?Met?Glu?Lys?Val?Pro?Pro?Asp?Trp?Glu?Arg?Ala?Ser?Phe

850 855 860caa?cag?ggc?agt?cag?gcc?agc?cct?gat?tta?aag?cca?agt?cca?caa?aat 2820Gln?Gln?Gly?Ser?Gln?Ala?Ser?Pro?Asp?Leu?Lys?Pro?Ser?Pro?Gln?Asn865 870 875 880gga?gcc?acg?ttc?ccg?tcc?tct?gga?gga?tat?ggc?cag?ggg?tca?ctg?ata 2868Gly?Ala?Thr?Phe?Pro?Ser?Ser?Gly?Gly?Tyr?Gly?Gln?Gly?Ser?Leu?Ile

885 890 895gcc?gat?gag?gag?tcc?cag?gag?ttt?gat?gat?tta?ata?ttt?gca?tta?aaa 2916Ala?Asp?Glu?Glu?Ser?Gln?Glu?Phe?Asp?Asp?Leu?Ile?Phe?Ala?Leu?Lys

900 905 910act?ggt?gct?ggt?ctc?agt?gtc?agt?gat?aat?gaa?tct?ggt?caa?ggc?agc 2964Thr?Gly?Ala?Gly?Leu?Ser?Val?Ser?Asp?Asn?Glu?Ser?Gly?Gln?Gly?Ser

915 920 925cag?gag?ggg?ggc?acc?ttg?act?gac?tcc?cag?atc?gtg?gag?ctc?agg?agg 3012Gln?Glu?Gly?Gly?Thr?Leu?Thr?Asp?Ser?Gln?Ile?Val?Glu?Leu?Arg?Arg

930 935 940ata?ccc?atc?gcc?gac?act?cac?ctg?tag?cacctcacta?accattcgac 3059Ile?Pro?Ile?Ala?Asp?Thr?His?Leu945 950tgagcacact?ttcatatttg?tatcagcttt?tgtgctaaaa?ctctctaagt?acatccacct 3119gtgtaatagg?aacctgtgaa?ttgtactgga?tgattaatac?aaacgtgatt?gttgtatttg 3179gagtataaat?tactgattgt?atgtgacctg?aaaattcact?gctataagaa?aggtggagtc 3239agtttgtatc?agttaatagg?atgttcatat?tccaaggata?ttagttgttt?ttttaatcat 3299cctatatggc?taacattgtt?taatgaaagt?aataatcaat?aaagcaatag?aa 3351<210>2<211>952<212>PRT<213>Homo?sapiens<400>2Met?Val?Ile?Ile?Thr?Gly?Ser?Asp?Leu?His?Asn?Gly?Ile?Ile?Gly?Phe1 5 10 15Ser?Glu?Glu?Ser?Gln?Ser?Gly?Leu?Glu?Leu?Arg?Glu?Gly?Ala?Val?Met

20 25 30Arg?Arg?Leu?His?Leu?Ile?Val?Thr?Arg?Gln?Pro?Asn?Arg?Ala?Phe?Glu

35 40 45Asp?Val?Lys?Val?Phe?Trp?Arg?Val?Thr?Leu?Asn?Lys?Thr?Val?Val?Val

50 55 60Leu?Gln?Lys?Asp?Gly?Val?Asn?Leu?Met?Glu?Glu?Leu?Gln?Ser?Val?Ser65 70 75 80Gly?Thr?Thr?Thr?Cys?Thr?Met?Gly?Gln?Thr?Lys?Cys?Phe?Ile?Ser?Ile

85 90 95Glu?Leu?Lys?Pro?Glu?Lys?Val?Pro?Gln?Val?Glu?Val?Tyr?Phe?Phe?Val

100 105 110Glu?Leu?Tyr?Glu?Ala?Thr?Ala?Gly?Ala?Ala?Ile?Asn?Asn?Ser?Ala?Arg

115 120 125Phe?Ala?Gln?Ile?Lys?Ile?Leu?Glu?Ser?Asp?Glu?Ser?Gln?Ser?Leu?Val

130 135 140Tyr?Phe?Ser?Val?Gly?Ser?Arg?Leu?Ala?Val?Ala?His?Lys?Lys?Ala?Thr145 150 155 160Leu?Ile?Ser?Leu?Gln?Val?Ala?Arg?Asp?Ser?Gly?Thr?Gly?Leu?Met?Met

165 170 175Ser?Val?Asn?Phe?Ser?Thr?Gln?Glu?Leu?Arg?Ser?Ala?Glu?Thr?Ile?Gly

180 185 190Arg?Thr?Ile?Ile?Ser?Pro?Ala?Ile?Ser?Gly?Lys?Asp?Phe?Val?Ile?Thr

195 200 205Glu?Gly?Thr?Leu?Val?Phe?Glu?Pro?Gly?Gln?Arg?Ser?Thr?Val?Leu?Asp

210 215 220Val?Ile?Leu?Thr?Pro?Glu?Thr?Gly?Ser?Leu?Asn?Ser?Phe?Pro?Lys?Arg225 230 235 240Phe?Gln?Ile?Val?Leu?Phe?Asp?Pro?Lys?Gly?Gly?Ala?Arg?Ile?Asp?Lys

245 250 255Val?Tyr?Gly?Thr?Ala?Asn?Ile?Thr?Leu?Val?Ser?Asp?Ala?Asp?Ser?Gln

260 265 270Ala?Ile?Trp?Gly?Leu?Ala?Asp?Gln?Leu?His?Gln?Pro?Val?Asn?Asp?Asp

275 280 285Ile?Leu?Asn?Arg?Val?Leu?His?Thr?Ile?Ser?Met?Lys?Val?Ala?Thr?Glu

290 295 300Asn?Thr?Asp?Glu?Gln?Leu?Ser?Ala?Met?Met?His?Leu?Ile?Glu?Lys?Ile305 310 315 320Thr?Thr?Glu?Gly?Lys?Ile?Gln?Ala?Phe?Ser?Val?Ala?Ser?Arg?Thr?Leu

325 330 335Phe?Tyr?Glu?Ile?Leu?Cys?Ser?Leu?Ile?Asn?Pro?Lys?Arg?Lys?Asp?Thr

340 345 350Arg?Gly?Phe?Ser?His?Phe?Ala?Glu?Val?Thr?Glu?Asn?Phe?Ala?Phe?Ser

355 360 365Leu?Leu?Thr?Asn?Val?Thr?Cys?Gly?Ser?Pro?Gly?Glu?Lys?Ser?Lys?Thr

370 375 380Ile?Leu?Asp?Ser?Cys?Pro?Tyr?Leu?Ser?Ile?Leu?Ala?Leu?His?Trp?Tyr385 390 395 400Pro?Gln?Gln?Ile?Asn?Gly?His?Lys?Phe?Glu?Gly?Lys?Glu?Gly?Asp?Tyr

405 410 415Ile?Arg?Ile?Pro?Glu?Arg?Leu?Leu?Asp?Val?Gln?Asp?Ala?Glu?Ile?Met

420 425 430Ala?Gly?Lys?Ser?Thr?Cys?Lys?Leu?Val?Gln?Phe?Thr?Glu?Tyr?Ser?Ser

435 440 445Gln?Gln?Trp?Phe?Ile?Ser?Gly?Asn?Asn?Leu?Pro?Thr?Leu?Lys?Asn?Lys

450 455 460Val?Leu?Ser?Leu?Ser?Val?Lys?Gly?Gln?Ser?Ser?Gln?Leu?Leu?Thr?Asn465 470 475 480Asp?Asn?Glu?Val?Leu?Tyr?Arg?Ile?Tyr?Ala?Ala?Glu?Pro?Arg?Ile?Ile

485 490 495Pro?Gln?Thr?Ser?Leu?Cys?Leu?Leu?Trp?Asn?Gln?Ala?Ala?Ala?Ser?Trp

500 505 510Leu?Ser?Asp?Ser?Gln?Phe?Cys?Lys?Val?Val?Glu?Glu?Thr?Ala?Asp?Tyr

515 520 525Val?Glu?Cys?Ala?Cys?Ser?His?Met?Ser?Val?Tyr?Ala?Val?Tyr?Ala?Arg

530 535 540Thr?Asp?Asn?Leu?Ser?Ser?Tyr?Asn?Glu?Ala?Phe?Phe?Thr?Ser?Gly?Phe545 550 555 560Ile?Cys?Ile?Ser?Gly?Leu?Cys?Leu?Ala?Val?Leu?Ser?His?Ile?Phe?Cys

565 570 575Ala?Arg?Tyr?Ser?Met?Phe?Ala?Ala?Lys?Leu?Leu?Thr?His?Met?Met?Ala

580 585 590Ala?Ser?Leu?Gly?Thr?Gln?Ile?Leu?Phe?Leu?Ala?Ser?Ala?Tyr?Ala?Ser

595 600 605Pro?Gln?Leu?Ala?Glu?Glu?Ser?Cys?Ser?Ala?Met?Ala?Ala?Val?Thr?His

610 615 620Tyr?Leu?Tyr?Leu?Cys?Gln?Phe?Ser?Trp?Met?Leu?Ile?Gln?Ser?Val?Asn625 630 635 640Phe?Trp?Tyr?Val?Leu?Val?Met?Asn?Asp?Glu?His?Thr?Glu?Arg?Arg?Tyr

645 650 655Leu?Leu?Phe?Phe?Leu?Leu?Ser?Trp?Gly?Leu?Pro?Ala?Phe?Val?Val?Ile

660 665 670Leu?Leu?Ile?Val?Ile?Leu?Lys?Gly?Ile?Tyr?His?Gln?Ser?Met?Ser?Gln

675 680 685Ile?Tyr?Gly?Leu?Ile?His?Gly?Asp?Leu?Cys?Phe?Ile?Pro?Asn?Val?Tyr

690 695 700Ala?Ala?Leu?Phe?Thr?Ala?Ala?Leu?Val?Pro?Leu?Thr?Cys?Leu?Val?Val705 710 715 720Val?Phe?Val?Val?Phe?Ile?His?Ala?Tyr?Gln?Val?Lys?Pro?Gln?Trp?Lys

725 730 735Ala?Tyr?Asp?Asp?Val?Phe?Arg?Gly?Arg?Thr?Asn?Ala?Ala?Glu?Ile?Pro

740 745 750Leu?Ile?Leu?Tyr?Leu?Phe?Ala?Leu?Ile?Ser?Val?Thr?Trp?Leu?Trp?Gly

755 760 765Gly?Leu?His?Met?Ala?Tyr?Arg?His?Phe?Trp?Met?Leu?Val?Leu?Phe?Val

770 775 780Ile?Phe?Asn?Ser?Leu?Gln?Gly?Leu?Tyr?Val?Phe?Met?Val?Tyr?Phe?Ile785 790 795 800Leu?His?Asn?Gln?Met?Cys?Cys?Pro?Met?Lys?Ala?Ser?Tyr?Thr?Val?Glu

805 810 815Met?Asn?Gly?His?Pro?Gly?Pro?Ser?Thr?Ala?Phe?Phe?Thr?Pro?Gly?Ser

820 825 830Gly?Met?Pro?Pro?Ala?Gly?Gly?Glu?Ile?Ile?Lys?Ser?Thr?Gln?Asn?Leu

835 840 845Ile?Gly?Ala?Met?Glu?Lys?Val?Pro?Pro?Asp?Trp?Glu?Arg?Ala?Ser?Phe

850 855 860Gln?Gln?Gly?Ser?Gln?Ala?Ser?Pro?Asp?Leu?Lys?Pro?Ser?Pro?Gln?Asn865 870 875 880Gly?Ala?Thr?Phe?Pro?Ser?Ser?Gly?Gly?Tyr?Gly?Gln?Gly?Ser?Leu?Ile

885 890 895Ala?Asp?Glu?Glu?Ser?Gln?Glu?Phe?Asp?Asp?Leu?Ile?Phe?Ala?Leu?Lys

900 905 910Thr?Gly?Ala?Gly?Leu?Ser?Val?Ser?Asp?Asn?Glu?Ser?Gly?Gln?Gly?Ser

915 920 925Gln?Glu?Gly?Gly?Thr?Leu?Thr?Asp?Ser?Gln?Ile?Val?Glu?Leu?Arg?Arg

930 935 940Ile?Pro?Ile?Ala?Asp?Thr?His?Leu945 950<210>3<211>23<212>DNA<213>Homo?sapiens<400>3gaagaacaaa ctcttaccct tat23<210>4<211>23<212>DNA<213>Homo?sapiens<400>4ttctattgct ttattgatta tta23<210>5<211>33<212>DNA<213>Homo?sapiens<400>5cccggatcca tggttattat tacagggagt gac33<210>6<211>33<212>DNA<213>Homo?sapiens<400>6cccctcgagc tcagtcgaat ggttagtgag gag33

Claims (18)

1, a kind of isolated polypeptide-people's transposase 105 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in＜210〉2 or the active fragments of its polypeptide, analogue or derivative.

2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in＜210〉2.

3, polypeptide as claimed in claim 2 is characterized in that it comprises and has＜polypeptide of the aminoacid sequence shown in 210〉2.

4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:

(a) coding have＜210〉2 shown in the polynucleotide of the polypeptide of aminoacid sequence or its fragment, analogue, derivative;

(b) with polynucleotide (a) complementary polynucleotide; Or

(c) with (a) or the polynucleotide of at least 98% homogeny (b) are arranged.

5, polynucleotide as claimed in claim 4, it is characterized in that described polynucleotide comprise coding and have＜210〉2 shown in the polynucleotide of aminoacid sequence.

6, polynucleotide as claimed in claim 4, it is characterized in that the sequence of described polynucleotide includes＜210〉1 in the 181-3039 position sequence or＜210〉1 in the sequence of 1-3351 position.

7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.

8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:

(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or

(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.

9, a kind of preparation method with people's transposase 105 active polypeptide is characterized in that described method comprises:

(a) under expressing human transposase 105 conditions, cultivate the described through engineering approaches host cell of claim 8;

(b) from culture, isolate and have people's transposase 105 active polypeptide.

10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with people's transposase 105 specificity bonded antibody.

11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses people's transposase 105.

12, compound as claimed in claim 11 is characterized in that it is＜polynucleotide sequence or its segmental antisense sequences shown in 210〉1.

13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used for mediator's transposase 105 in vivo, the method for external activity.

14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.

15, as the application of polypeptide as described in the arbitrary claim among the claim 1-3, it is characterized in that it is applied to screen the stand-in of people's transposase 105, agonist, antagonist or inhibitor; Perhaps be used for the peptide finger print identification.

16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.

17,, it is characterized in that forming pharmaceutical composition with safe and effective dosage and pharmaceutically acceptable carrier as the relevant unusually disease of diagnosis or treatment and people's transposase 105 with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.

18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11, it is characterized in that being used for the treatment of as malignant tumour with described polypeptide, polynucleotide or compound, hemopathy, the medicine of HIV infection and immunological disease and all kinds of inflammation.